September 12, 2021
NervGen is not an investment for the faint of heart, but for those investors who like to bet on trailblazing biotech companies with truly novel, disease modifying, science, and moonshot […]
June 7, 2021
As the company “Pivots” from development to commercial stage, we believe shareholders could reap outsized returns. Read More.
February 22, 2021
We believe by 2023, Processa could have one, or more, programs in Ph3, warranting a substantial bump in valuation, which we estimate to be >$500mm. Read More.
November 9, 2020
Low Science / High Science, Low Risk / High Risk, Ocuphire has a little of everything, heading into a data-rich 2021. Read More.
October 21, 2020
We believe Perimeter’s widefield OCT unit, OTIS, can be a solution to the reexcision “epidemic” in breast conservation surgery. Read More.
May 19, 2020
We believe Delcath’s $50mm market cap today is a reflection of its colorful past, not its bright future. Read More.
October 16, 2019
We believe through clinical success with their lead assets, XEN496 and XEN1101, Xenon can achieve a market cap of >$1 billion by 2021, reflecting a nearly 4.5x multiple from its […]